Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
St. |
RCV001543120 | SCV001761637 | uncertain significance | Multiple congenital exostosis | 2021-06-24 | criteria provided, single submitter | clinical testing | The EXT2 c.725+3A>C intronic change results from a A to C substitution at the +3 position of intron 4 of the EXT2 gene. Splice predictors are not conclusive as to whether or not this variant affects splicing and loss of function of the resulting protein product. RNA data demonstrates aberrant splicing in ~6-7% of mutant reads (internal data). This variant has a maximum subpopulation frequency of 0.0023% in gnomAD v2.1.1 (PM2_Supporting; https://gnomad.broadinstitute.org/variant/11-44130836-A-C?dataset=gnomad_r2_1). In summary, this variant meets criteria to be classified as of uncertain significance based on the ACMG/AMP criteria: PM2_Supporting. |
Gene |
RCV001564582 | SCV001787767 | uncertain significance | not provided | 2021-04-14 | criteria provided, single submitter | clinical testing | Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis supports a deleterious effect on splicing; Has not been previously published as pathogenic or benign to our knowledge |
Mayo Clinic Laboratories, |
RCV001564582 | SCV005412312 | uncertain significance | not provided | 2024-08-19 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005040311 | SCV005683541 | uncertain significance | Exostoses, multiple, type 2; Seizures-scoliosis-macrocephaly syndrome | 2024-02-02 | criteria provided, single submitter | clinical testing |